Mechanism of drug induced ferroptosis in the treatment of head and neck tumors

doi:10.3760/cma.j.cn371439-20210922-00029

Abstract

Abstract:

Ferroptosis is drived by lipid reactive oxygen species, which plays an important role in the development of tumors. It has been found that a variety of clinical medicines, such as artemisinin derivatives, itraconazole, sulfasala zine, cucurbitacin B, paclitaxel, disulfiram/copper can induce ferroptosis and inhibit tumor growth in head and neck cancer (HNC) through different mechanisms. To study the regulatory mechanism of ferroptosis induced by commonly used drugs in the treatment of HNC can provide reference for the targeted treatment of ferroptosis in HNC.

Key words: Head and neck neoplasms, Ferroptosis, Clinical medicine, Mechanism

Zeng Yan, Luo Pan, Wang Ziqi, Wu Weili. Mechanism of drug induced ferroptosis in the treatment of head and neck tumors[J]. Journal of International Oncology, 2022, 49(3): 173-176.

References 31

[1]	Johnson DE, Burtness B, Leemans CR, et al. Head and neck squamous cell carcinoma[J]. Nat Rev Dis Primers, 2020, 6(1):92. DOI: 10.1038/s41572-020-00224-3. doi: 10.1038/s41572-020-00224-3 pmid: 33243986
[2]	Stockwell BR, Jiang X, Gu W. Emerging mechanisms and disease relevance of ferroptosis[J]. Trends Cell Biol, 2020, 30(6):478-490. DOI: 10.1016/j.tcb.2020.02.009. doi: S0962-8924(20)30054-4 pmid: 32413317
[3]	Xie Y, Hou W, Song X, et al. Ferroptosis: process and function[J]. Cell Death Differ, 2016, 23(3):369-379. DOI: 10.1038/cdd.2015.158. doi: 10.1038/cdd.2015.158 pmid: 26794443
[4]	Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer[J]. Cancer Cell, 2019, 35(6):830-849. DOI: 10.1016/j.ccell.2019.04.002. doi: S1535-6108(19)30197-7 pmid: 31105042
[5]	Alvarez SW, Sviderskiy VO, Terzi EM, et al. NFS1 undergoes positive selection in lung tumours and protects cells from ferroptosis[J]. Nature, 2017, 551(7682):639-643. DOI: 10.1038/nature24637. doi: 10.1038/nature24637
[6]	Seiler A, Schneider M, Förster H, et al. Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase depen-dent- and AIF-mediated cell death[J]. Cell Metab, 2008, 8(3):237-248. DOI: 10.1016/j.cmet.2008.07.005. doi: 10.1016/j.cmet.2008.07.005
[7]	Efferth T. From ancient herb to modern drug: artemisia annua and artemisinin for cancer therapy[J]. Semin Cancer Biol, 2017, 46:65-83. DOI: 10.1016/j.semcancer.2017.02.009. doi: S1044-579X(17)30029-9 pmid: 28254675
[8]	Lin R, Zhang Z, Chen L, et al. Dihydroartemisinin (DHA) induces ferroptosis and causes cell cycle arrest in head and neck carcinoma cells[J]. Cancer Lett, 2016, 381(1):165-175. DOI: 10.1016/j.canlet.2016.07.033. doi: 10.1016/j.canlet.2016.07.033
[9]	Roh JL, Kim EH, Jang H, et al. Nrf2 inhibition reverses the resis-tance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis[J]. Redox Biol, 2017, 11:254-262. DOI: 10.1016/j.redox.2016.12.010. doi: 10.1016/j.redox.2016.12.010
[10]	Zhang W, Bhagwath AS, Ramzan Z, et al. Itraconazole exerts its antitumor effect in esophageal cancer by suppressing the HER2/AKT signaling pathway[J]. Mol Cancer Ther, 2021, 20(10):1904-1915. DOI: 10.1158/1535-7163.MCT-20-0638. doi: 10.1158/1535-7163.MCT-20-0638 pmid: 34376577
[11]	Takahashi S, Karayama M, Takahashi M, et al. Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan with concomitant ritonavir or itraconazole in patients with HER2-expressing advanced solid tumors[J]. Clin Cancer Res, 2021, 27(21):5771-5780. DOI: 10.1158/1078-0432.CCR-21-1560. doi: 10.1158/1078-0432.CCR-21-1560
[12]	Buczacki SJA, Popova S, Biggs E, et al. Itraconazole targets cell cycle heterogeneity in colorectal cancer[J]. J Exp Med, 2018, 215(7):1891-1912. DOI: 10.1084/jem.20171385. doi: 10.1084/jem.20171385
[13]	Gerber DE, Putnam WC, Fattah FJ, et al. Concentration-dependent early antivascular and antitumor effects of itraconazole in non-small cell lung cancer[J]. Clin Cancer Res, 2020, 26(22):6017-6027. DOI: 10.1158/1078-0432.CCR-20-1916. doi: 10.1158/1078-0432.CCR-20-1916
[14]	Xu Y, Wang Q, Li X, et al. Itraconazole attenuates the stemness of nasopharyngeal carcinoma cells via triggering ferroptosis[J]. Environ Toxicol, 2021, 36(2):257-266. DOI: 10.1002/tox.23031. doi: 10.1002/tox.23031
[15]	Zhao B, Li X, Wang Y, et al. Iron-dependent cell death as executioner of cancer stem cells[J]. J Exp Clin Cancer Res, 2018, 37(1):79. DOI: 10.1186/s13046-018-0733-3. doi: 10.1186/s13046-018-0733-3
[16]	Ji X, Qian J, Rahman SMJ, et al. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression[J]. Oncogene, 2018, 37(36):5007-5019. DOI: 10.1038/s41388-018-0307-z. doi: 10.1038/s41388-018-0307-z
[17]	Shin D, Kim EH, Lee J, et al. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer[J]. Free Radic Biol Med, 2018, 129:454-462. DOI: 10.1016/j.freeradbiomed.2018.10.426. doi: 10.1016/j.freeradbiomed.2018.10.426
[18]	Pouillon L, Bossuyt P, Vanderstukken J, et al. Management of patients with inflammatory bowel disease and spondyloarthritis[J]. Expert Rev Clin Pharmacol, 2017, 10(12):1363-1374. DOI: 10.1080/17512433.2017.1377609. doi: 10.1080/17512433.2017.1377609
[19]	Gout PW, Buckley AR, Simms CR, et al. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)-cystine transporter: a new action for an old drug[J]. Leukemia, 2001, 15(10):1633-1640. DOI: 10.1038/sj.leu.2402238. doi: 10.1038/sj.leu.2402238 pmid: 11587223
[20]	Kim EH, Shin D, Lee J, et al. CISD2 inhibition overcomes resis-tance to sulfasalazine-induced ferroptotic cell death in head and neck cancer[J]. Cancer Lett, 2018, 432:180-190. DOI: 10.1016/j.canlet.2018.06.018. doi: 10.1016/j.canlet.2018.06.018
[21]	Yuan R, Zhao W, Wang QQ, et al. Cucurbitacin B inhibits non-small cell lung cancer in vivo and in vitro by triggering TLR4/NLRP3/GSDMD-dependent pyroptosis[J]. Pharmacol Res, 2021, 170:105748. DOI: 10.1016/j.phrs.2021.105748. doi: 10.1016/j.phrs.2021.105748
[22]	Bakar-Ates F, Ozkan E, Sengel-Turk CT. Encapsulation of cucur-bitacin B into lipid polymer hybrid nanocarriers induced apoptosis of MDAMB231 cells through PARP cleavage[J]. Int J Pharm, 2020, 586:119565. DOI: 10.1016/j.ijpharm.2020.119565. doi: 10.1016/j.ijpharm.2020.119565
[23]	Wang K, Ye H, Zhang X, et al. An exosome-like programmable-bioactivating paclitaxel prodrug nanoplatform for enhanced breast cancer metastasis inhibition[J]. Biomaterials, 2020, 257:120224. DOI: 10.1016/j.biomaterials.2020.120224. doi: 10.1016/j.biomaterials.2020.120224
[24]	Tao B, Wang D, Yang S, et al. Cucurbitacin B inhibits cell proli-feration by regulating X-inactive specific transcript expression in tongue cancer[J]. Front Oncol, 2021, 11:651648. DOI: 10.3389/fonc.2021.651648. doi: 10.3389/fonc.2021.651648
[25]	Huang S, Cao B, Zhang J, et al. Induction of ferroptosis in human nasopharyngeal cancer cells by cucurbitacin B: molecular mechanism and therapeutic potential[J]. Cell Death Dis, 2021, 12(3):237. DOI: 10.1038/s41419-021-03516-y. doi: 10.1038/s41419-021-03516-y
[26]	Jiang L, Kon N, Li T, et al. Ferroptosis as a p53-mediated activity during tumour suppression[J]. Nature, 2015, 520(7545):57-62. DOI: 10.1038/nature14344. doi: 10.1038/nature14344
[27]	Ou Y, Wang SJ, Li D, et al. Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses[J]. Proc Natl Acad Sci U S A, 2016, 113(44):E6806-E6812. DOI: 10.1073/pnas.1607152113. doi: 10.1073/pnas.1607152113
[28]	Wen G, Qu XX, Wang D, et al. Recent advances in design, synjournal and bioactivity of paclitaxel-mimics[J]. Fitoterapia, 2016, 110:26-37. DOI: 10.1016/j.fitote.2016.02.010. doi: 10.1016/j.fitote.2016.02.010
[29]	Ye J, Jiang X, Dong Z, et al. Low-concentration PTX and RSL3 inhibits tumor cell growth synergistically by inducing ferroptosis in mutant p53 hypopharyngeal squamous carcinoma[J]. Cancer Manag Res, 2019, 11:9783-9792. DOI: 10.2147/CMAR.S217944. doi: 10.2147/CMAR.S217944
[30]	McMahon A, Chen W, Li F. Old wine in new bottles: advanced drug delivery systems for disulfiram-based cancer therapy[J]. J Control Release, 2020, 319:352-359. DOI: 10.1016/j.jconrel.2020.01.001. doi: 10.1016/j.jconrel.2020.01.001
[31]	Li Y, Chen F, Chen J, et al. Disulfiram/copper induces antitumor activity against both nasopharyngeal cancer cells and cancer-associa-ted fibroblasts through ROS/MAPK and ferroptosis pathways[J]. Cancers (Basel), 2020, 12(1):138. DOI: 10.3390/cancers12010138. doi: 10.3390/cancers12010138